Trial Profile
A single-dose, randomized, open-label, two-treatment, three-period, three-sequence, partial replicate crossover trial to study relative bioavailability study of the grazoprevir/elbasvir fixed-dose combination in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2016
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 20 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics